Skip to Content
Merck
  • Expression of FAM83H and ZNF16 are associated with shorter survival of patients with gallbladder carcinoma.

Expression of FAM83H and ZNF16 are associated with shorter survival of patients with gallbladder carcinoma.

Diagnostic pathology (2020-05-29)
Sung Woo Ahn, Ae-Ri Ahn, Sang Hoon Ha, Usama Khamis Hussein, Jae Do Yang, Kyoung Min Kim, Ho Sung Park, See-Hyoung Park, Hee Chul Yu, Kyu Yun Jang
ABSTRACT

Recently, FAM83H was reported to have roles in cancer progression in conjunction with oncogenic molecules such as MYC and b-catenin. Moreover, the data from the public database indicates a molecular relationship between FAM83H and zinc finger proteins, especially between FAM83H and ZNF16. However, studies on FAM83H and ZNF16 in gallbladder cancer have been limited. This study investigated the expression of FAM83H and ZNF16 in 105 gallbladder carcinomas. In human gallbladder carcinomas, immunohistochemical expression of FAM83H was significantly associated with ZNF16 expression. In univariate analysis, nuclear and cytoplasmic expression of FAM83H or ZNF16 were significantly associated with shorter survival of gallbladder carcinoma patients. Multivariate analysis revealed the nuclear expression of FAM83H as an independent indicator of poor prognosis of overall survival (p = 0.005) and relapse-free survival (p = 0.005) of gallbladder carcinoma patients. Moreover, co-expression patterns of nuclear FAM83H and ZNF16 were also independent indicators of shorter survival of gallbladder carcinoma patients (overall survival; p <  0.001, relapse-free survival; p <  0.001). This study suggests FAM83H and ZNF16 are associated with the progression of gallbladder carcinoma, and the expressions of FAM83H and ZNF16 might be novel prognostic indicators of gallbladder carcinoma patients.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
MISSION® esiRNA, targeting human FAM83H